CASE REPORT
A 48-year-old white man (90 kg) tested HIV-positive in April 1997. At that time, he had an HIV-RNA (viral load) of 100 × 10 3 copies/mL and a CD4+ cell count of 300 × 1 0 6 /L. Figure 1 shows all relevant data, in chronological ordered, of what happened thereafter. The patient started triple therapy consisting of indinavir 800 mg q8h, lamivudine 150 mg bid, and zidovudine 200 mg tid in May (HIV-RNA 200 × 1 0 3 copies/mL). After one month, the HIV-RNA had dropped from 200 × 1 0 3 to 2 × 10 3 c o p i e s / m L . Three weeks later, he stopped therapy because of personal reasons and did not resume antiretroviral therapy for five months. At the end of November, he restarted the same triple combination. At that time, the HIV-RNA was 70 × 10 3 copies/mL with a CD4+ cell count of 190 × 1 0 6 /L. After two months of therapy, the HIV-RNA was undetectable (<400 copies/mL), which was confirmed one month later. The CD4+ cell counts at these times were 340 and 400 × 1 0 6 /L, respectively. In the first week of April 1998, the HIV-RNA was detectable again (6 × 1 0 3 c o p i e s / m L ) , with a further increase to 300 × 10 3 copies/mL in July. The CD4+ cell count had decreased to 200 × 1 0 6 /L at that time. In August, a new regimen was started containing nevirapine, didanosine, and stavudine, which produced satisfactory response; after one month, the HIV-RNA was 3 × 1 0 3 copies/mL and the CD4+ cell count was 420 × 1 0 6 / L .
During the second period of triple therapy (December 1997), the patient developed herpes zoster. He was first treated with famciclovir; tramadol was added to treat the postherpetic neuralgia. Tramadol was discontinued because the patient did not experience adequate analgesia; carbamazepine 200 mg/d was started in mid-January 1998. Carbamazepine was discontinued at the end of March; tramadol was restarted due to insufficient clinical response to carbamazepine and complaints of drowsiness.
Indinavir plasma concentrations are monitored routinely in patients treated in our hospital. Concentrations are determined by a validated RP-HPLC method, 5 after which the concentration ratio is calculated by dividing each patient's indinavir plasma concentration by the average value in a reference population at the same time point after ingestion (reference population, n = 14, AUC 0 -8 h 19.3 mg/L•h, maximum concentration 8.6 mg/L, minimum concentration 0.14 mg/L). 1 Before carbamazepine was started, the indinavir concentrations were slightly below the lower limit of the mean population curve ± 2 SEM. The two samples drawn during carbamazepine therapy were much lower (25% and 4% of the mean population values). Carbamazepine concentrations, measured by fluorescence polarization immunoassay technology (Abbott, Chicago, IL), were within the therapeutic window for epilepsy treatment, which is probably higher than expected for the low dose given to our patient. Approximately two weeks after carbamazepine was discontinued, the indinavir concentration was higher than the mean; just before the indinavir triple combination was stopped, the plasma concentration was again at the lower limit of the mean curve ± 2 SEM. Looking at the actual plasma concentrations, the following comparison can be made: in the sample in 1997, which was taken 4.5 hours after ingestion, the indinavir concentration was 0.45 mg/L (reference population 0.88 mg/L). No comparison with other samples at this time point can be made. Two samples were drawn at ±2.75 hours after ingestion: the first, before carbamazepine was started, was 2.0 mg/L (reference population 3.3 mg/L), the second, during carbamazepine therapy (3 wk), was 0.9 mg/L. Three samples were drawn at ±3.75 hours after ingestion (2.2 times lower than before carbamazepine). The concentration before carbamazepine was 1.1 mg/L (reference population 1.6 mg/L), the one during carbamazepine (7 wk) was 0.07 mg/L (16 times lower), and the third, shortly after withdrawal of carbamazepine, was 2.6 mg/L (2.4 times higher than the concentration before carbamazepine). These data show that comparing plasma data at similar intervals after ingestion results in lower plasma concentrations (up to 16 times lower) when carbamazepine is administered. Even though the community pharmacist notified the physician of the possible interaction between carbamazepine and indinavir and the indi-navir concentrations were low during carbamazepine therapy, no dosage adjustment of indinavir was made.
Based on the low indinavir concentrations and the consecutive increase in HIV-RNA under triple therapy pressure, resistance was expected. Genotypic resistance analysis was performed using an automated sequencer (ABI 377, PE Biosystems, Foster City, CA) and Big-Dye-terminator chemistry (PE Biosystems). Population sequencing of the entire protease gene and of the RT gene from amino acid 1 to approximately 300 was performed using polymerase chain reaction amplified genome fragments derived from plasma virus RNA. 6 The baseline serum samples (November 1997), as well as those obtained in April 1998 (HIV-RNA 6 × 1 0 3 copies/mL) and July 1998 (HIV-RNA 300 × 1 0 3 copies/mL), were analyzed.
The virus was completely wildtype for lamivudine, zidovudine, and indinavir in November 1997. However, in April 1998 the lamivudine resistance mutation (M184V) was detected as a mixture with the wildtype, and for zidovudine a complex heterogenic genotype was observed at codon 215, among which the resistance mutation might have been present. No resistance mutations of indinavir were detected. In July 1998, no resistance mutations of lamivudine, zidovudine, or indinavir were detected.
During the use of indinavir, our patient was using other medications; however, he was receiving only oxazepam and carbamazepine when the indinavir plasma concentrations were very low (February and March 1998). Oxazepam was used the whole time the patient was taking indinavir except August 1998; oxazepam is not expected to lower indinavir concentrations. Other drugs that were used concomitantly with indinavir were an amitriptyline analog (June 1997), temazepam (June 1997, April and August 1998), and tramadol (January and April 1998). None of these drugs lower indinavir concentrations, which is reflected in the concentration ratios. 2 In addition to the insufficient indinavir plasma concentrations during carbamazepine therapy, poor compliance could be an explanation for the treatment failure. For that reason, a detailed analysis on compliance was performed: the AIDS-specialist nurse estimated that the patient was compliant after an extensive interview; the physician believed the patient was compliant; pharmacy records in combination with prescription data and the interview with the patient did not suggest noncompliance; no specific notes about noncompliance were found in the medical record; plasma concentrations of indinavir were detectable; and ingestion times documented on the plasma sample collection forms showed differences in ingestion times over the follow-up period, indicating that the patient reported real ingestion times. Based on these data, there was no reason for us to doubt the patient's compliance, except for missing a dose approximately once a month.
The interaction was probable according to the Naranjo 7 s c a l e ; however, four of the 10 items on the scale were not applicable to this case report.
D i s c u s s i o n
Carbamazepine is associated with numerous interactions when given concomitantly with other drugs 8 ; howeve r, carbamazepine concentrations often are the only ones closely monitored.
Carbamazepine is predominantly metabolized by CYP-3A4; CYP2C9 and CYP1A2 play a less important role. The CYP3A4 route is responsible for the production of the active metabolite carbamazepine-10,11-epoxide.
Inhibition of CYP3A4 by drugs such as ketoconazole, cimetidine, macrolide antibiotics, and HIV-protease inhibitors may increase carbamazepine concentrations into the toxic range. We suspected this in our patient when he reported drowsiness and when his carbamazepine concen-trations were in the upper half of the therapeutic range for e p i l e p s y, although a low dose of carbamazepine had been prescribed.
Carbamazepine can have a strong effect on plasma concentrations of certain drugs due to induction of CYP3A and possibly other cytochrome P450 subtypes. Concentrations of indinavir in our patient were decreased to 25% and 4% of the population values at two consecutive measurements; without carbamazepine, these ratios were approximately within the normal range or higher. HIV-protease inhibitors are predominantly metabolized by CYP3A4; C Y P 2 D 6 and CYP2C9 contribute to the metabolism as w e l l . 9 Inducers of these enzymes, such as carbamazepine, may therefore produce subtherapeutic protease inhibitor concentrations.
When indinavir concentrations were decreased in our patient, only two-drug therapy was given, which appeared to be insufficient to fully suppress the virus, allowing lamivudine resistance to develop. It has been reported 1 0 -1 2 t h a t with a rise in the HIV-RNA resistance for reverse transcriptase inhibitors occurs earlier than it does for protease inhibitors. This may be due to the large selective benefit that occurs with the lamivudine M184V mutation compared with resistance mutations observed with protease inhibitors. Once the M184V mutation appears, the mutated virus has a 1000-fold selective benefit compared with the wildtype virus, while for indinavir, single or double mutations do not appear to result in a measurable reduction in s u s c e p t i b i l i t y. 1 3 Our patient developed herpes zoster shortly after starting highly active antiretroviral therapy, which has been previosuly described. 3 After the acute treatment of the infection, the HIV-RNA was undetectable; therefore, the herpes infection does not explain the increased HIV-RNA that developed a few months later.
If we assume that the patient complied with the antiretroviral regimen, significantly lower indinavir concentrations, caused by the interaction between carbamazepine and indinavir, is the most likely explanation for the increased HIV-RNA and the development of lamivudine resistance. The question here is what would be the optimal treatment for postherpetic neuralgia for a patient on combination antiretroviral therapy containing protease inhibitors. The same question applies for HIV-infected patients who have seizures due to, for example, toxoplasmosis infection. Carbamazepine therapy is often considered an option but, based on what occurred in our patient, that may not be the best choice. Based on the data presented in this case report and taking into account what can be expected when carbamazepine is given with protease inhibitors, the combination of these drugs should be avoided. Pharmacokinetic studies are needed to establish whether it is feasible to overcome subtherapeutic indinavir concentrations by starting with higher indinavir and lower carbamazepine dosages, and to make further dosage adjustments based on therapeutic drug monitoring. However, clinicians should first choose alternatives for carbamazepine. Table 1 lists several treatment options for postherpetic neuralgia and
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The Annals of Pharmacotherapy s 2000 April, Volume 34 s 4 6 7 w w w . t h e a n n a l s . c o m epilepsy and the possible interactions of these agents with protease inhibitors. Based on the data in this table, amitriptyline or gabapentin can be used for postherpetic neuralgia, and valproic acid or lamotrigine can be used as anticonvulsants; therapy should be monitored for toxicity of amitrip-tyline and efficacy of valproic acid or lamotrigine. There are a few other options (e.g., nortriptyline or aspirin for postherpetic neuralgia or gabapentin for epilepsy), but clinical experience and proof of efficacy are limited or the risk of interaction is unclear. 
S u m m a ry
The interaction between carbamazepine and indinavir in our patient significantly lowered indinavir plasma concentrations, which are assumed to be subtherapeutic. This interaction apparently caused insufficient viral suppression, resulting in an increase in HIV-RNA and the development of lamivudine resistance. When carbamazepine was discontinued and indinavir concentrations returned to norm a l , the HIV-RNA still increased. These results show that carbamazepine and indinavir should not be combined. This, theoretically, also applies for the other HIV-protease inhibitors.
P h a rmacokinetic studies are needed to establish whether it is feasible to overcome subtherapeutic indinavir concentrations in this combination therapy by starting with a higher indinavir dosage and a lower carbamazepine dosage, and to make further dosage adjustments based on therapeutic drug monitoring. However, replacing the interacting drug with a drug that has a lower interaction risk is preferred. Carbamazepine might be substituted for gabapentin or amitriptyline in the treatment of postherpetic neuralgia; valproic acid or lamotrigine are alternatives for carbamazepine if an anticonvulsant is needed.
